OmniAb Beheer
Beheer criteriumcontroles 2/4
De CEO OmniAb is Matt Foehr, benoemd in Nov2022, heeft een ambtstermijn van 3.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.81M, bestaande uit 16.3% salaris en 83.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.05% van de aandelen van het bedrijf, ter waarde $ 11.27M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.4 jaar en 3.5 jaar.
Belangrijke informatie
Matt Foehr
Algemeen directeur
US$3.8m
Totale compensatie
| Percentage CEO-salaris | 16.29% |
| Dienstverband CEO | 3.5yrs |
| Eigendom CEO | 3.0% |
| Management gemiddelde ambtstermijn | 3.4yrs |
| Gemiddelde ambtstermijn bestuur | 3.5yrs |
Recente managementupdates
Recent updates
Narratiefupdate • May 15
OABI: 2026 Revenue Guidance And Margin Outlook Will Drive Long Term Upside
Analysts have updated their price target on OmniAb, maintaining their fair value estimate at $7.33 while refining assumptions for the discount rate, revenue growth, profit margins, and future P/E to reflect revised expectations for the business. What's in the News OmniAb issued earnings guidance for 2026, setting an expected revenue range of US$25 million to US$30 million.Narratiefupdate • Apr 27
OABI: Updated Bylaws And 2026 Guidance Will Support Long Term Upside
Analysts have nudged their OmniAb price target slightly higher to $170.16 from $162.92, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E levels. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million.Narratiefupdate • Apr 08
OABI: Updated Bylaws And 2026 Revenue Guidance Will Support Long Term Upside
Analysts kept their price target on OmniAb broadly aligned with prior views, citing relatively steady assumptions around fair value, growth and profitability that offset only minor tweaks to the discount rate and future P/E multiple. What's in the News OmniAb issued earnings guidance for 2026, with expected revenue in a range of $25 million to $30 million, giving you a reference point for the company’s own outlook on its top line for that year (Key Developments).Narratiefupdate • Mar 25
OABI: Updated Governance And 2026 Revenue Outlook Will Support Long Term Upside
Analysts kept their fair value estimate for OmniAb steady at $7.33 while making only very small tweaks to assumptions such as discount rate, revenue growth, profit margin and future P/E. This reflects a largely unchanged view of the stock’s longer term risk and earnings potential.Narratiefupdate • Mar 08
OABI: New Discovery Platform And Guidance Will Support Long Term Upside Potential
Analysts have modestly revised their price target on OmniAb, reflecting updated assumptions around long term revenue growth, profit margins, and future P/E expectations. Specific dollar values for the target change have not been disclosed.Narratiefupdate • Feb 21
OABI: New Discovery Platform Will Support Stronger Long Term Upside Potential
Analysts have lowered their Omn iAb price target to $7.33 per share, citing slightly reduced profit margin assumptions and a modestly higher future P/E multiple, while keeping long-term revenue growth expectations broadly unchanged. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that became effective the same day, updating the company’s governance framework.Narratiefupdate • Feb 06
OABI: New Antibody Platform And Governance Changes Will Drive Future Upside
Analysts have modestly trimmed their price targets on OmniAb, citing slightly higher discount rate assumptions along with a small uplift in expected profit margins and future P/E levels as the key drivers of the recalibration. What's in the News On January 30, 2026, OmniAb's board approved amended and restated bylaws that took effect the same day, updating company rules and governance procedures.Narratiefupdate • Jan 22
OABI: New Antibody Discovery Platform And Partnerships Will Drive Future Upside
Analysts have maintained their OmniAb price target at US$7.33, making only minor adjustments to assumptions such as the discount rate, long-term profit margin, and future P/E. These changes fine tune their valuation view rather than significantly revising it.Narratiefupdate • Jan 08
OABI: New Antibody Platform Launch Will Drive Future Upside Potential
Analysts have lifted their price target on OmniAb to reflect updated assumptions for revenue growth of 41.53%, profit margin of 15.66% and a future P/E of 173.35x, which together suggest a slightly higher required return of 7.93% compared with prior inputs. What's in the News OmniAb launched its new OmniUltra platform at the 2025 Antibody Engineering & Therapeutics Conference in San Diego, describing it as a transgenic chicken system designed to generate human antibodies with ultralong CDRH3 domains and very small picobodies for a range of therapeutic uses, including bispecifics, multispecifics, CAR-T, radioligands and peptide therapeutics (Key Developments).Narratiefupdate • Dec 16
OABI: Future Platform Launch And Partnerships Will Drive Revenue Upside
Narrative Update on OmniAb Analysts have maintained their price target on OmniAb at approximately 7.33 dollars, reflecting only marginal adjustments to the discount rate and profitability assumptions, while leaving their long-term growth outlook largely unchanged. What's in the News OmniAb plans to debut its new OmniUltra trademark transgenic chicken platform in December 2025 at the Antibody Engineering & Therapeutics conference.Narratiefupdate • Dec 02
OABI: New Partnerships And Fundraising Will Support Revenue Expansion Ahead
OmniAb’s analyst price target remains unchanged at $7.33 per share. Analysts note that minor adjustments in profit margin and discount rate projections were not sufficient to alter their outlook on the company's value.Narratiefupdate • Nov 18
OABI: Future Earnings and Margin Expansion Are Expected to Drive Share Upside
Analysts have lowered their price target for OmniAb from $7.86 to $7.33, citing updated expectations for higher revenue growth and profit margins. They also noted that an increased discount rate and a higher future price-to-earnings multiple were influencing factors.Analyseartikel • Oct 10
OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...Analyseartikel • Aug 09
Analyst Estimates: Here's What Brokers Think Of OmniAb, Inc. (NASDAQ:OABI) After Its Second-Quarter Report
NasdaqGM:OABI 1 Year Share Price vs Fair Value Explore OmniAb's Fair Values from the Community and select yours...Analyseartikel • Jul 09
Market Participants Recognise OmniAb, Inc.'s (NASDAQ:OABI) Revenues Pushing Shares 38% Higher
OmniAb, Inc. ( NASDAQ:OABI ) shares have had a really impressive month, gaining 38% after a shaky period beforehand...Seeking Alpha • May 12
OmniAb: Too Much Risk, Not Enough Reward
Summary OmniAb's innovative business model relies on licensing transgenic animals for drug discovery, but financial success hinges on partner drug approvals, which have been slow. Nearly three quarters of the late-stage pipeline's value is concentrated in just a single drug, IMVT-1402. OmniAb faces a cash burn issue, with operating expenses likely to outpace royalties for years before late-stage candidates meaningfully contribute. The FDA's shift away from animal trials threatens OmniAb's core business model, making the stock expensive and risky; I rate it a Sell. Read the full article on Seeking AlphaAnalyseartikel • May 11
Earnings Release: Here's Why Analysts Cut Their OmniAb, Inc. (NASDAQ:OABI) Price Target To US$7.88
It's shaping up to be a tough period for OmniAb, Inc. ( NASDAQ:OABI ), which a week ago released some disappointing...Analyseartikel • Apr 20
OmniAb, Inc. (NASDAQ:OABI) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, OmniAb, Inc. ( NASDAQ:OABI ) shares are down a considerable 29% in the last...
Nieuw narratief • Mar 29
Novel Technologies And Clinical Pipeline Will Unlock Future Possibilities
Strong growth in partners and programs suggests robust future milestone and royalty revenues as technologies attract significant opportunities.Analyseartikel • Nov 15
OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Have Been Cutting Their Estimates
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...Analyseartikel • Sep 14
Is OmniAb (NASDAQ:OABI) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Analyseartikel • Jul 15
Are Investors Undervaluing OmniAb, Inc. (NASDAQ:OABI) By 43%?
Key Insights OmniAb's estimated fair value is US$7.87 based on 2 Stage Free Cash Flow to Equity Current share price of...Analyseartikel • May 12
The OmniAb, Inc. (NASDAQ:OABI) First-Quarter Results Are Out And Analysts Have Published New Forecasts
OmniAb, Inc. ( NASDAQ:OABI ) just released its latest quarterly report and things are not looking great. It was not a...Analyseartikel • Mar 26
Things Look Grim For OmniAb, Inc. (NASDAQ:OABI) After Today's Downgrade
Today is shaping up negative for OmniAb, Inc. ( NASDAQ:OABI ) shareholders, with the analysts delivering a substantial...Analyseartikel • Feb 28
Revenues Not Telling The Story For OmniAb, Inc. (NASDAQ:OABI)
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 11.4x may look like a poor investment opportunity...Analyseartikel • Jan 15
OmniAb, Inc.'s (NASDAQ:OABI) Intrinsic Value Is Potentially 37% Above Its Share Price
Key Insights The projected fair value for OmniAb is US$8.52 based on 2 Stage Free Cash Flow to Equity OmniAb's US$6.22...Analyseartikel • Nov 11
Unpleasant Surprises Could Be In Store For OmniAb, Inc.'s (NASDAQ:OABI) Shares
OmniAb, Inc.'s ( NASDAQ:OABI ) price-to-sales (or "P/S") ratio of 7.6x may look like a poor investment opportunity when...Analyseartikel • Aug 13
Earnings Update: OmniAb, Inc. (NASDAQ:OABI) Just Reported And Analysts Are Trimming Their Forecasts
The analysts might have been a bit too bullish on OmniAb, Inc. ( NASDAQ:OABI ), given that the company fell short of...Analyseartikel • May 14
OmniAb, Inc. (NASDAQ:OABI) Analysts Just Cut Their EPS Forecasts Substantially
One thing we could say about the analysts on OmniAb, Inc. ( NASDAQ:OABI ) - they aren't optimistic, having just made a...Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$54m |
| Dec 31 2025 | US$4m | US$621k | -US$65m |
| Sep 30 2025 | n/a | n/a | -US$64m |
| Jun 30 2025 | n/a | n/a | -US$64m |
| Mar 31 2025 | n/a | n/a | -US$61m |
| Dec 31 2024 | US$4m | US$594k | -US$62m |
| Sep 30 2024 | n/a | n/a | -US$63m |
| Jun 30 2024 | n/a | n/a | -US$62m |
| Mar 31 2024 | n/a | n/a | -US$63m |
| Dec 31 2023 | US$3m | US$564k | -US$51m |
| Sep 30 2023 | n/a | n/a | -US$30m |
| Jun 30 2023 | n/a | n/a | -US$27m |
| Mar 31 2023 | n/a | n/a | -US$22m |
| Dec 31 2022 | US$7m | US$542k | -US$22m |
| Sep 30 2022 | n/a | n/a | -US$32m |
| Jun 30 2022 | n/a | n/a | -US$28m |
| Mar 31 2022 | n/a | n/a | -US$25m |
| Dec 31 2021 | US$5m | US$519k | -US$27m |
| Sep 30 2021 | n/a | n/a | -US$24m |
| Dec 31 2020 | US$3m | US$504k | -US$18m |
Compensatie versus markt: De totale vergoeding ($USD 3.81M ) Matt } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.67M ).
Compensatie versus inkomsten: De vergoeding van Matt is gestegen terwijl het bedrijf verliesgevend is.
CEO
Matt Foehr (52 yo)
3.5yrs
Tenure
US$3,811,740
Compensatie
Mr. Matthew W. Foehr, also known as Matt, has been the President, Chief Executive Officer and Director of OmniAb, Inc. since November 1, 2022. Mr. Foehr has been the Chief Executive Officer and President a...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3.5yrs | US$3.81m | 3.05% $ 11.3m | |
| Executive VP of Finance & CFO | 3.5yrs | US$1.61m | 0.18% $ 666.8k | |
| Chief Legal Officer & Secretary | 3.5yrs | US$1.62m | 0.28% $ 1.0m | |
| Senior Vice President of People & Talent | 3.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Antibody Discovery | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Antibody Technologies | no data | geen gegevens | geen gegevens | |
| Senior Vice President of Exploratory Research | 1.3yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Discovery Systems | less than a year | geen gegevens | geen gegevens | |
| Vice President of Business Development & Strategy | no data | geen gegevens | geen gegevens |
3.4yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van OABI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 3.5yrs | US$3.81m | 3.05% $ 11.3m | |
| Chairman | 3.5yrs | US$150.69k | 2.03% $ 7.5m | |
| Independent Director | 3.5yrs | US$148.19k | 0.064% $ 237.9k | |
| Independent Director | 2.5yrs | US$151.59k | 0.049% $ 182.7k | |
| Independent Director | 1.1yrs | US$253.82k | 0.0092% $ 34.0k | |
| Independent Director | 1.1yrs | US$254.95k | 0.0092% $ 34.0k | |
| Independent Director | 3.5yrs | US$148.19k | 0.11% $ 393.2k |
3.5yrs
Gemiddelde duur
55yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van OABI wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/05/22 00:51 |
| Aandelenkoers aan het einde van de dag | 2026/05/22 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
OmniAb, Inc. wordt gevolgd door 9 analisten. 7 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Robert Wasserman | Benchmark Company |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |